<unk>  is a rare malignant vascular neoplasm of endothelial-type cells that line vessel walls. The peak age of incidence appears to be the 7th decade, and men are affected more commonly than women.<unk>  was first described by Dr. Juan Rosai, in 1976. The pathogenesis of<unk>  is characterized by a rapid and extensively infiltrating overgrowth of vascular endothelial cells.<unk>  may arise in any part of the body, but is more common in soft tissues than in bones. Common<unk>  locations include the  head and neck area, kidney, liver, lung, and and the most common site of radiation-induced<unk>  development is the breast.  The PTPRB/PLCG1 genes are associated with the development of<unk> ; mutation of these genes result in aberrant angiogenesis. The imaging modality of choice for diagnosing<unk>  will depend on the location. For pulmonary<unk> , the imaging modality of choice is CT scan with intravenous contrast. For other types<unk> , the imaging modality of choice is MRI. On CT scan, findings suggestive of<unk>  may include vascular invasion, nodular enhancement (common), and a hypoattenuating mass. The mainstay adjuvant therapy for<unk>  is a doxorubicin-based regimen. The response rate for chemotherapy in patients with<unk>  is poor.
Angiosarcoma
Hemangioma
Angiokeratoma
Lymphangiosarcoma
Sarcoma
Lymphangioma
Angioma
Liposarcoma